Investigational A3 adenosine receptor targeting agents

Expert Opinion on Investigational Drugs

Volumn 20, Issue 6, 2011, Pages 757-768

  Koscsó, Balázs ^a   Csóka, Balázs ^a   Pacher, Pál ^b   Haskó, György ^a,c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

A3 adenosine receptor; asthma; cancer; IB MECA; rheumatoid arthritis

Indexed keywords

1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 2 CHLORO 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 6 ETHYL 2 PHENYL 4 PROPYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR ANTAGONIST; CP 532 903; CP 532903; METHOTREXATE; MRS 1067; MRS 1334; UNCLASSIFIED DRUG; VUF 5574; ADENOSINE A3 RECEPTOR AGONIST; LIGAND;

ASTHMA; BRAIN ISCHEMIA; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DRUG EFFECT; DRUG TARGETING; DRY EYE; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FAILURE; KIDNEY ISCHEMIA; MAST CELL; MELANOMA; NEOPLASM; NEUTROPHIL; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; IMMUNOLOGY; IMMUNOPATHOLOGY; METABOLISM; PATHOPHYSIOLOGY;

ADENOSINE A3 RECEPTOR AGONISTS; ADENOSINE A3 RECEPTOR ANTAGONISTS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNE SYSTEM DISEASES; LIGANDS; RECEPTOR, ADENOSINE A3;

EID: 79955809218     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.573785     Document Type: Review

References (121)

1. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004;25(1):33-9 (Pubitemid 38032805)
2. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7(9):759-70
3. Hasko G, Pacher P, Vizi ES, Illes P. Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 2005;26(10):511-16 (Pubitemid 41338561)
4. Hasko G, Pacher P, Deitch EA, Vizi ES. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther 2007;113(2):264-75 (Pubitemid 46149045)
5. Hasko G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 2008;83(3):447-55 (Pubitemid 351966849)
6. Hasko G, Csoka B, Nemeth ZH, et al. A(2B) adenosine receptors in immunity and inflammation. Trends Immunol 2009;30(6):263-70
7. Csoka B, Nemeth ZH, Rosenberger P, et al. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol 2010;185(1):542-50
8. Fredholm BB, Ap IJ, Jacobson KA, et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53(4):527-52 (Pubitemid 33136237)
9. Bours MJL, Swennen ELR, Di Virgilio F, et al. Adenosine 5¢-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006;112(2):358-404 (Pubitemid 44486409)
10. Sajjadi FG, Boyle DL, Domingo RC, Firestein GS. cDNA cloning and characterization of A3i, an alternatively spliced rat A3 adenosine receptor variant. FEBS Lett 1996;382(1-2):125-9 (Pubitemid 26092243)
11. Gessi S, Merighi S, Varani K, et al. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 2008;117(1):123-40 (Pubitemid 350192673)
12. Muller CE. Medicinal chemistry of adenosine A(3) receptor ligands. Curr Top Med Chem 2003;3(4):445-62
13. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5(3):247-64 (Pubitemid 43336037)
14. Jacobson KA. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 1998;19(5):184-91 (Pubitemid 28255405)
15. Jacobson KA, Park KS, Jiang JL, et al. Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology 1997;36(9):1157-65 (Pubitemid 27465604)
16. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 2003;15(9):813-27 (Pubitemid 36776656)
17. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006;6(3):173-82 (Pubitemid 43290987)
18. Chen Y, Corriden R, Inoue Y, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006;314(5806):1792-5 (Pubitemid 44969094)
19. Inoue Y, Chen Y, Hirsh MI, et al. A3 and P2Y2 receptors control the recruitment of neutrophils to the lungs in a mouse model of sepsis. Shock 2008;30(2):173-7
20. van der Hoeven D, Wan TC, Auchampach JA. Activation of the A3 adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Mol Pharmacol 2008;74(3):685-96
21. van der Hoeven D, Gizewski ET, Auchampach JA. Activation of the A3 adenosine receptor inhibits fMLP-induced Rac activation in mouse bone marrow neutrophils. Biochem Pharmacol;79(11):1667-73
22. Sajjadi FG, Takabayashi K, Foster AC, et al. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol 1996;156(9):3435-42 (Pubitemid 26124449)
23. McWhinney CD, Dudley MW, Bowlin TL, et al. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur J Pharmacol 1996;310(2-3):209-16 (Pubitemid 26298264)
24. Hasko G, Nemeth ZH, Vizi ES, et al. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. Eur J Pharmacol 1998;358(3):261-8 (Pubitemid 28498186)
25. Lee JY, Jhun BS, Oh YT, et al. Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-[alpha] production through inhibition of PI 3-kinase/Akt and NF-[kappa]B activation in murine BV2 microglial cells. Neurosci Lett 2006;396(1):1-6 (Pubitemid 43233777)
26. Martin L, Pingle SC, Hallam DM, et al. Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther 2006;316(1):71-8 (Pubitemid 41832582)
27. Hasko G, Kuhel DG, Chen JF, et al. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 2000;14(13):2065-74
28. Hasko G, Szabo C, Nemeth ZH, et al. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996;157(10):4634-40 (Pubitemid 126449386)
29. Kreckler LM, Wan TC, Ge ZD, Auchampach JA. Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther 2006;317(1):172-80
30. Szabo C, Scott GS, Virag L, et al. Suppression of macrophage inflammatory protein (MIP)-1 alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998;125(2):379-87 (Pubitemid 28425204)
31. Barnholt KE, Kota RS, Aung HH, Rutledge JC. Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. J Immunol 2009;183(10):6767-77
32. Broussas M, Cornillet-Lefebvre P, Potron G, Nguyen P. Inhibition of fMLP-triggered respiratory burst of human monocytes by adenosine: involvement of A3 adenosine receptor. J Leukoc Biol 1999;66(3):495-501 (Pubitemid 29439258)
33. Thiele A, Kronstein R, Wetzel A, et al. Regulation of adenosine receptor subtypes during cultivation of human monocytes: role of receptors in preventing lipopolysaccharide-triggered respiratory burst. Infect Immun 2004;72(3):1349-57 (Pubitemid 38263755)
34. Velot E, Haas B, Léonard FDR, et al. Activation of the adenosine-A3 receptor stimulates matrix metalloproteinase-9 secretion by macrophages. Cardiovasc Res 2008;80(2):246-54
35. Panther E, Idzko M, Herouy Y, et al. Expression and function of adenosine receptors in human dendritic cells. FASEB J 2001;15(11):1963-70 (Pubitemid 32848800)
36. Dickenson JM, Reeder S, Rees B, et al. Functional expression of adenosine A2A and A3 receptors in the mouse dendritic cell line XS-106. Eur J Pharmacol 2003;474(1):43-51 (Pubitemid 37289144)
37. Ben Addi A, Lefort A, Hua X, et al. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur J Immunol 2008;38(6):1610-20
38. Novitskiy SV, Ryzhov S, Zaynagetdinov R, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 2008;112(5):1822-31
39. Wilson JM, Ross WG, Agbai ON, et al. The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol 2009;182(8):4616-23
40. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol 2007;7(2):93-104 (Pubitemid 46174857)
41. Ramkumar V, Stiles GL, Beaven MA, Ali H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 1993;268(23):16887-90 (Pubitemid 23236909)
42. Reeves JJ, Jones CA, Sheehan MJ, et al. Adenosine A3 receptors promote degranulation of rat mast cells both in vitro and in vivo. Inflamm Res 1997;46(5):180-4 (Pubitemid 27248399)
43. Zhong H, Shlykov SG, Molina JG, et al. Activation of murine lung mast cells by the adenosine A3 receptor. J Immunol 2003;171(1):338-45 (Pubitemid 36745306)
44. Smith SR, Denhardt G, Terminelli C. A role for histamine in cytokine modulation by the adenosine A(3) receptor agonist, 2-Cl-IB-MECA. Eur J Pharmacol 2002;457(1):57-69 (Pubitemid 35379976)
45. Salvatore CA, Tilley SL, Latour AM, et al. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 2000;275(6):4429-34 (Pubitemid 30094686)
46. Feoktistov I, Biaggioni I. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 1995;96(4):1979-86
47. Ryzhov S, Goldstein AE, Matafonov A, et al. Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 2004;172(12):7726-33 (Pubitemid 38747640)
48. Jin X, Shepherd RK, Duling BR, Linden J. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest 1997;100(11):2849-57 (Pubitemid 28007555)
49. Tilley SL, Wagoner VA, Salvatore CA, et al. Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. J Clin Invest 2000;105(3):361-7 (Pubitemid 30094456)
50. Gao Z, Li BS, Day YJ, Linden J. A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol 2001;59(1):76-82 (Pubitemid 32043088)
51. Feoktistov I, Ryzhov S, Goldstein AE, Biaggioni I. Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors. Circ Res 2003;92(5):485-92 (Pubitemid 36368660)
52. Gessi S, Varani K, Merighi S, et al. Expression of A(3) adenosine receptors in human lymphocytes: up-regulation in T cell activation. Mol Pharmacol 2004;65(3):711-19
53. Csoka B, Himer L, Selmeczy Z, et al. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J 2008;22(10):3491-9
54. MacKenzie WM, Hoskin DW, Blay J. Adenosine inhibits the adhesion of anti-CD3-activated killer lymphocytes to adenocarcinoma cells through an A3 receptor. Cancer Res 1994;54(13):3521-6 (Pubitemid 24225977)
55. Hoskin DW, Butler JJ, Drapeau D, et al. Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int J Cancer 2002;99(3):386-95 (Pubitemid 34498302)
56. Harish A, Hohana G, Fishman P, et al. A3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol 2003;23(4):1245-9
57. Jeffe F, Stegmann KA, Broelsch F, et al. Adenosine and IFN-{alpha} synergistically increase IFN-gamma production of human NK cells. J Leukoc Biol 2009;85(3):452-61
58. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010;69(11):1898-906
59. Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol 2010;10(8):605-11
60. Montesinos MC, Takedachi M, Thompson LF, et al. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5¢-nucleotidase: findings in a study of ecto-5¢-nucleotidase gene-deficient mice. Arthritis Rheum 2007;56(5):1440-5 (Pubitemid 46764071)
61. Madi L, Cohen S, Ochayin A, et al. Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. J Rheumatol 2007;34(1):20-6 (Pubitemid 46106558)
62. Ochaion A, Bar-Yehuda S, Cohen S, et al. The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell Immunol 2009;258(2):115-22
63. Varani K, Massara A, Vincenzi F, et al. Normalization of A(2A) and A(3) Adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. Arthritis Rheum 2009;60(10):2880-91
64. Baharav E, Bar-Yehuda S, Madi L, et al. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 2005;32(3):469-76 (Pubitemid 40381417)
65. Fishman P, Bar-Yehuda S, Madi L, et al. The PI3K-NF-kappa B signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther 2006;8(1):R33
66. Ochaion A, Bar-Yehuda S, Cohen S, et al. The A(3) adenosine receptor agonist CF502 inhibits the PI3K, PKB/ Akt and NF-kappa B signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol 2008;76(4):482-94
67. Ochaion A, Bar-Yehuda S, Cohn S, et al. Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. Arthritis Res Ther 2006;8(6):R169
68. Bar-Yehuda S, Rath-Wolfson L, Del Valle L, et al. Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis Rheum 2009;60(10):3061-71
69. Silverman MH, Strand V, Markovits D, et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol 2008;35(1):41-8
70. Driver AG, Kukoly CA, Ali S, Mustafa SJ. Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis 1993;148(1):91-7 (Pubitemid 23187224)
71. Huszar A, Vass G, Vizi A, et al. Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma. Eur Respir J 2002;20(6):1393-8 (Pubitemid 35469046)
72. Cushley MJ, Tattersfield AE, Holgate ST. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol 1983;15(2):161-5 (Pubitemid 13184390)
73. Walker BA, Jacobson MA, Knight DA, et al. Adenosine A3 receptor expression and function in eosinophils. Am J Respir Cell Mol Biol 1997;16(5):531-7 (Pubitemid 127498285)
74. Knight D, Zheng X, Rocchini C, et al. Adenosine A3 receptor stimulation inhibits migration of human eosinophils. J Leukoc Biol 1997;62(4):465-8 (Pubitemid 27459775)
75. Ezeamuzie CI, Philips E. Adenosine A(3) receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release. Br J Pharmacol 1999;127(1):188-94 (Pubitemid 29213248)
76. Tilley SL, Tsai M, Williams CM, et al. Identification of A3 receptor-and mast cell-dependent and-independent components of adenosine-mediated airway responsiveness in mice. J Immunol 2003;171(1):331-7 (Pubitemid 36745305)
77. Hua X, Chason KD, Fredholm BB, et al. Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells. J Allergy Clin Immunol 2008;122(1):107-13, 13 e1-7
78. Young HW, Molina JG, Dimina D, et al. A3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J Immunol 2004;173(2):1380-9 (Pubitemid 38924319)
79. Young HW, Sun CX, Evans CM, et al. A3 adenosine receptor signaling contributes to airway mucin secretion after allergen challenge. Am J Respir Cell Mol Biol 2006;35(5):549-58 (Pubitemid 44706427)
80. Madi L, Ochaion A, Rath-Wolfson L, et al. The A(3) adenosine receptor is highly expressed in tumor versus normal cells: Potential target for tumor growth inhibition. Clin Cancer Res 2004;10(13):4472-9 (Pubitemid 38878891)
81. Gessi S, Cattabriga E, Avitabile A, et al. Elevated expression of A(3) adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 2004;10(17):5895-901 (Pubitemid 39180971)
82. Fishman P, Bar-Yehuda S, Ohana G, et al. An agonist to the A(3) adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene 2004;23(14):2465-71 (Pubitemid 38520744)
83. Bar-Yehuda S, Stemmer SM, Madi L, et al. The A(3) adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappa B signal transduction pathways. Int J Oncol 2008;33(2):287-95
84. Cohen S, Stemmer S, Zozulya G, et al. CF102 an A(3) adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol 2010. [Epub ahead of print]
85. Kim SJ, Min HY, Chung HJ, et al. Inhibition of cell proliferation through cell cycle arrest and apoptosis by thio-Cl-IB-MECA, a novel A3 adenosine receptor agonist, in human lung cancer cells. Cancer Lett 2008;264(2):309-15
86. Morello S, Petrella A, Festa M, et al. Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation. Cancer Biol Ther 2008;7(2):278-84 (Pubitemid 351590437)
87. Mlejnek P, Dolezel P. Induction of apoptosis by A3 adenosine receptor agonist N-(3-iodobenzyl)-adenosine-5¢-N-methylcarboxamide in human leukaemia cells: a possible involvement of intracellular mechanism. Acta Physiol (Oxf) 2010;199(2):171-9
88. Jajoo S, Mukherjea D, Watabe K, Ramkumar V. Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia 2009;11(11):1132-45
89. Ohana G, Bar-Yehuda S, Arich A, et al. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer 2003;89(8):1552-8 (Pubitemid 37386614)
90. Gessi S, Sacchetto V, Fogli E, et al. Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. Biochem Pharmacol 2010;79(10):1483-95
91. Gessi S, Merighi S, Varani K, et al. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. J Cell Physiol 2007;211(3):826-36 (Pubitemid 46683050)
92. Merighi S, Benini A, Mirandola P, et al. A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia 2005;7(10):894-903
93. Merighi S, Benini A, Mirandola P, et al. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol 2006;72(1):19-31 (Pubitemid 43795348)
94. Merighi S, Benini A, Mirandola P, et al. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 2007;72(2):395-406 (Pubitemid 47124120)
95. Wan TC, Ge ZD, Tampo A, et al. The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3¢-aminoadenosine-5¢-N- methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. J Pharmacol Exp Ther 2008;324(1):234-43 (Pubitemid 350294150)
96. Ge Z-D, der Hoeven Dv, Maas JE, et al. A3 adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells. J Mol Cell Cardiol;49(2):280-6
97. Jordan JE, Thourani VH, Auchampach JA, et al. A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol 1999;277(5 Pt 2):H1895-905
98. Pacher P, Liaudet L, Bai P, et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002;300(3):862-7 (Pubitemid 34164989)
99. Pacher P, Liaudet L, Mabley JG, et al. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med 2006;17(2):369-75
100. Mukhopadhyay P, Batkai S, Rajesh M, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 2007;50(6):528-36 (Pubitemid 47126779)
101. Mukhopadhyay P, Rajesh M, Batkai S, et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 2009;296(5):H1466-83
102. Mukhopadhyay P, Rajesh M, Batkai S, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res 2010;85(4):773-84
103. Mukhopadhyay P, Horvath B, Rajesh M, et al. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med 2011;50(1):179-95
104. Emanuelov AK, Shainberg A, Chepurko Y, et al. Adenosine A3 receptor-mediated cardioprotection against doxorubicin-induced mitochondrial damage. Biochem Pharmacol 2010;79(2):180-7
105. Chen GJ, Harvey BK, Shen H, et al. Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. J Neurosci Res 2006;84(8):1848-55 (Pubitemid 44892618)
106. Shen H, Chen GJ, Harvey BK, et al. Inosine reduces ischemic brain injury in rats. Stroke 2005;36(3):654-9 (Pubitemid 40344173)
107. Luo C, Yi B, Tao G, et al. Adenosine A3 receptor agonist reduces early brain injury in subarachnoid haemorrhage. Neuroreport 2010;21(13):892-6
108. Sei Y, vonLubitz DKJE, Abbracchio MP, et al. Adenosine A(2) receptor agonist-induced neurotoxicity in rat cerebellar granule neurons. Drug Develop Res 1997;40(3):267-73 (Pubitemid 27334339)
109. Appel E, Kazimirsky G, Ashkenazi E, et al. Roles of BCL-2 and caspase 3 in the adenosine A3 receptor-induced apoptosis. J Mol Neurosci 2001;17(3):285-92 (Pubitemid 34123945)
110. Vonlubitz DKJE, Lin RCS, Popik P, et al. Adenosine a(3) Receptor stimulation and cerebral-ischemia. Eur J Pharmacol 1994;263(1-2):59-67
111. Palmer TM, Harris CA, Coote J, Stiles GL. Induction of multiple effects on adenylyl cyclase regulation by chronic activation of the human A3 adenosine receptor. Mol Pharmacol 1997;52(4):632-40 (Pubitemid 27443985)
112. Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3receptors. Am J Physiol-Renal Physiol 2000;278(3):F380-F7 (Pubitemid 30163237)
113. Lee HT, Ota-Setlik A, Xu H, et al. A3 adenosine receptor knockout mice are protected against ischemia-and myoglobinuria-induced renal failure. Am J Physiol Renal Physiol 2003;284(2):F267-73 (Pubitemid 36114689)
114. Mabley J, Soriano F, Pacher P, et al. The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5¢-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol 2003;466(3):323-9 (Pubitemid 36412095)
115. Guzman J, Yu JG, Suntres Z, et al. ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis. Inflamm Bowel Dis 2006;12(8):766-89 (Pubitemid 44253762)
116. Antonioli L, Fornai M, Colucci R, et al. Control of enteric neuromuscular functions by purinergic A(3) receptors in normal rat distal colon and experimental bowel inflammation. Br J Pharmacol 2010;161(4):856-71
117. Wagner R, Ngamsri KC, Stark S, et al. Adenosine receptor A3 is a critical mediator in LPS-induced pulmonary inflammation. Am J Physiol Lung Cell Mol Physiol 2010;299(4):L502-12
118. Morschl E, Molina LG, Volmer JB, et al. A(3) adenosine receptor signaling influences pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2008;39(6):697-705
119. Mariette X, Gottenberg JE. Pathogenesis of Sjogren's syndrome and therapeutic consequences. Curr Opin Rheumatol 2010;22(5):471-7
120. Avni I, Garzozi HJ, Barequet IS, et al. Treatment of dry eye syndrome with orally administered cf101 data from a phase 2 clinical trial. Ophthalmology 2010;117(7):1287-93
121. Lee HT, Kim M, Joo JD, et al. A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol 2006;291(4):R959-69 (Pubitemid 44498436)